Clinical Trials

Accrual Status
Limit to SWOG Trials

1030 Results

    View
    Open
    Phase
    SWOG Clinical Trial Number
    MYELOMATCH

    Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials
    Research Committee(s)
    myeloMATCH
    Leukemia
    Activated
    05-16-2024
    ClinicalTrials.gov Registry Number
    NCT05564390
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    MM1YA-S01

    A Randomized Phase II Study Comparing Cytarabine +Daunurubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A myeloMATCH Clinical Trial
    Research Committee(s)
    myeloMATCH
    Leukemia
    Activated
    05-16-2024
    ClinicalTrials.gov Registry Number
    NCT05554406
    Open
    SWOG Clinical Trial Number
    S2303

    Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
    Research Committee(s)
    Gastrointestinal Cancer
    Activated
    05-06-2024
    ClinicalTrials.gov Registry Number
    06203600
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S1900K

    A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
    Status Notes
    S1900K will open to accrual December 18, 2023, effective 3:00 p.m. EST.
    Research Committee(s)
    LungMAP
    Activated
    12-18-2023
    ClinicalTrials.gov Registry Number
    NCT06031688
    Open
    Phase
    Accrual
    0%
    SWOG Clinical Trial Number
    S2213

    A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
    Status Notes
    S2213 is open to patient accrual December 01, 2023, effective 12:00 p.m. Pacific Time.
    Research Committee(s)
    Myeloma
    Activated
    12-01-2023
    ClinicalTrials.gov Registry Number
    06022939
    Open
    Phase
    Accrual
    2%
    SWOG Clinical Trial Number
    S2206

    A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
    Status Notes
    This study is open to patient accrual effective 10/30/23.
    Research Committee(s)
    Breast Cancer
    Symptom Control and Quality of Life
    Activated
    10-30-2023
    ClinicalTrials.gov Registry Number
    06058377